课题基金 / 基金详情

Multi-dimensional comparison of differentially pathogenic coronaviruses (CoV) in human lung tissue

Multi-dimensional comparison of differentially pathogenic coronaviruses (CoV) in human lung tissue
人肺组织中差异致病性冠状病毒(CoV)的多维度比较
批准号:
10377826
负责人:
Jeffrey R Johnson
金额:
$25.38万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-09-24 至 2023-08-31

项目摘要

项目成果

Jeffrey R Johnson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY: SARS-CoV-2 is a novel coronavirus and the cause of the current global pandemic. This outbreak started in December of 2019 and has now spread over the entire world. SARS-CoV-2 is a respiratory pathogen that causes COVID-19, which has been the cause of more than 2.6 million deaths worldwide, with over 538,000 deaths in the US alone as of March 2021. The primary pathology caused by SARS-CoV-2 infection in humans is in the lungs. In this proposal, we seek to study the early events following coronavirus infection by infecting human lung tissue ex vivo. In order to understand the mechanism by which SARS-CoV-2 causes such severe disease outcomes, we will compare two coronavirus strains, SARS-CoV-2 (which is highly pathogenic) and NL63 (which is mildly pathogenic) in humans. In Aim 1, we will identify differences in viral replication kinetics, infected cell types, and the inflammatory response. In Aim 2, we will characterize the host response to infection using mass spectrometry-based proteomics. Understanding these complex virus:host components in a human system and how these differ between coronaviruses will lead to new hypotheses for in vivo susceptibility and identify new drug targets for therapeutic development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Function interactions between mitogen-activated protein kinases (MAPKs) and SARS-CoV-2
Cellular Determinants and Function Consequences of PP2A-B56 Degradation by HIV-1 Vif
Characterizing chromatin protein dynamics in HIV-1 latency with a CASPEX approach
Characterizing chromatin protein dynamics in HIV-1 latency with a CASPEX approach
海外基金